Blair William & Co. IL Sells 534,524 Shares of Phreesia, Inc. (NYSE:PHR)

Blair William & Co. IL lowered its holdings in Phreesia, Inc. (NYSE:PHR - Free Report) by 78.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,450 shares of the company's stock after selling 534,524 shares during the period. Blair William & Co. IL owned approximately 0.25% of Phreesia worth $3,660,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in PHR. The Manufacturers Life Insurance Company raised its stake in shares of Phreesia by 3.3% during the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company's stock valued at $637,000 after purchasing an additional 905 shares during the period. MetLife Investment Management LLC increased its holdings in shares of Phreesia by 3.8% in the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company's stock valued at $701,000 after acquiring an additional 1,120 shares during the last quarter. R Squared Ltd bought a new stake in Phreesia during the fourth quarter valued at $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Phreesia by 9.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company's stock worth $319,000 after acquiring an additional 1,258 shares during the period. Finally, BankPlus Trust Department bought a new stake in shares of Phreesia in the 4th quarter worth approximately $34,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Amy Beth Vanduyn sold 1,311 shares of Phreesia stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $26.61, for a total transaction of $34,885.71. Following the completion of the sale, the senior vice president now owns 115,633 shares in the company, valued at $3,076,994.13. The trade was a 1.12 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Balaji Gandhi sold 28,759 shares of Phreesia stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $30.00, for a total transaction of $862,770.00. Following the sale, the chief financial officer now directly owns 116,174 shares of the company's stock, valued at $3,485,220. This represents a 19.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 164,269 shares of company stock worth $4,661,469. Company insiders own 5.80% of the company's stock.

Phreesia Stock Performance

Shares of PHR traded down $0.57 during trading hours on Friday, reaching $24.27. 774,052 shares of the company traded hands, compared to its average volume of 430,576. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $30.53. The stock has a market cap of $1.43 billion, a P/E ratio of -16.51 and a beta of 0.82. The stock's fifty day moving average is $27.16 and its 200 day moving average is $24.22. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price target on shares of Phreesia in a research note on Thursday, March 13th. Royal Bank of Canada raised Phreesia from a "sector perform" rating to an "outperform" rating and boosted their price objective for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. Piper Sandler reiterated an "overweight" rating and issued a $33.00 price target (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Canaccord Genuity Group raised their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Finally, Truist Financial boosted their target price on shares of Phreesia from $31.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $31.33.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.